Bernstein China Pharma & Biotech: ASCO 2026 Part 3 - Summary
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Bernstein notes that market sentiment surrounding Chinese pharmaceutical and biotech companies has shifted from concept-driven speculation toward fundamentals, as highlighted by clinical data presentations at ASCO 2026. The firm expects stock performance to diverge over the next twelve months, with high-quality clinical data and commercialization capabilities driving premiums for industry leaders.
BeiGene received an Outperform rating with a target price of HKD 250, supported by superior overall survival data for zanubrutinib in CLL. Innovent Biologics is also rated Outperform with a target of HKD 60, benefiting from successful label expansions for sintilimab in first-line NSCLC. Toripalimab by Junshi Biosciences gained FDA approval for nasopharyngeal carcinoma, earning an Market-Perform rating and a HKD 40 target due to lingering commercial uncertainties.
Zai Lab holds a Market-Perform rating with a target of HKD 30, as niraparib faces looming generic competition. CanSino Biologics was assigned an Underperform rating with a target of HKD 20, reflecting slow vaccine pipeline progress. Bernstein emphasizes that investors should prioritize cash flow and differentiation in innovation over relying solely on clinical reads, while monitoring regulatory and medical insurance pricing pressures.
Key exhibits
Exhibit 1
Exhibit 2
Exhibit 3
Exhibit 4
Exhibit 5
Exhibit 6
Exhibit 7
Exhibit 8
